Free Trial
NYSE:BIO.B

Bio-Rad Laboratories (BIO.B) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$284.88 0.00 (0.00%)
As of 09/23/2025

About Bio-Rad Laboratories Stock (NYSE:BIO.B)

Advanced

Key Stats

Today's Range
$284.88
$284.88
50-Day Range
$247.05
$289.13
52-Week Range
$225.29
$359.22
Volume
20 shs
Average Volume
70 shs
Market Capitalization
$7.75 billion
P/E Ratio
24.29
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive BIO.B Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIO.B Stock News Headlines

Capital Gains Tax Strategies for Seniors
Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.tc pixel
Bio-Rad Labs B (BIOb) Earnings Dates & Reports
Bio-Rad price target lowered to $409 from $430 at RBC Capital
See More Headlines

BIO.B Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $325.60 at the beginning of 2025. Since then, BIO.B shares have decreased by 12.5% and is now trading at $284.8750.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) posted its earnings results on Thursday, July, 31st. The company reported $2.61 EPS for the quarter. Bio-Rad Laboratories had a net margin of 12.50% and a trailing twelve-month return on equity of 4.01%.

Bio-Rad Laboratories subsidiaries include Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, QuantaLife, DiaMed Holding AG, Blackhawk Biosystems, and others.

Shares of BIO.B stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
7/31/2025
Today
9/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Measuring And Control Equipment
Current Symbol
NYSE:BIO.B
CIK
12208
Employees
8,200
Year Founded
1952

Profitability

EPS (Trailing Twelve Months)
$11.73
Trailing P/E Ratio
24.29
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.84 billion
Net Margins
12.50%
Pretax Margin
17.62%
Return on Equity
4.01%
Return on Assets
2.82%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
5.12
Quick Ratio
3.67

Sales & Book Value

Annual Sales
$2.57 billion
Price / Sales
3.02
Cash Flow
$10.39 per share
Price / Cash Flow
27.41
Book Value
$234.52 per share
Price / Book
1.21

Miscellaneous

Outstanding Shares
27,210,000
Free Float
19,490,000
Market Cap
$7.75 billion
Optionable
Not Optionable
Beta
0.78

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NYSE:BIO.B) was last updated on 9/25/2025 by MarketBeat.com Staff
From Our Partners